Future IBD treatments out of sync with patient needs, expert says
EXPERT ANALYSIS FROM 2015 ADVANCES IN IBD
Potential new inflammatory bowel disease treatments
Adhesion molecule–based therapies
• PF-00547659 (Pfizer), an anti-MAdCam S1P1 agonist; an oral agent; for ulcerative colitis
• Ozanimod (Celgene); for ulcerative colitis; now in phase III
• Etrolizumab (Hoffmann-La Roche); for Crohn’s disease; now in phase III
Biologics for IL-12/23 pathways
MEDI2070 (MedImmune/Amgen), an anti-p19 antibody; targets IL-23 for Crohn’s disease
Agents for the JAK-STAT pathway
• Mongersen (Celgene), an oral SMAD7 antisense oligonucleotide; for Crohn’s disease; in phase III
• Tofacitinib (Pfizer)
Sources: Dr. Brian Feagan, University of Western Ontario; Dr. Bruce Sands, Mount Sinai School of Medicine; Dr. Bill Sandborn, University of California, San Diego
On Twitter @whitneymcknight
